Abstract 70P
Background
The safety and efficacy of intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct plus laparoscopic cholecystectomy (ENBD+ LC+ LCBD) for cholecystolithiasis combined with common bile duct stones (CBD stones) are uncertain.
Methods
The meta-analysis search was performed using PUBMED, OVID, EMBASE, and Cochrane database. All studies comparing ENBD+ LC+ LCBD and ECRP/EST+ LC from 1990 to 2018 were included. Pooled effect was calculated using the fixed and random effects models when necessary.
Results
A total of 5 trails included 700 patients with two different treatments (ENBD+ LC+ LCBD and ECRP/EST+ LC) were identified. The ENBD+ LC+ LCBD group had less total complications or adverse events (RR = 0.268, 95% CI:0.138–0.520, I2=0.0%, P < 0.001). And subgroup analysis of total complications exposed that although ENBD+ LC+ LCBD group developed more of biliary leak, there was no significance (RR = 3.890, 95% CI:0.88–17.25, I2=0.0%, P = 0.074). Meanwhile, there were lower rates of retained stones (RR = 0.272, 95% CI:0.09–0.85, I2=0.0%, P = 0.026), postoperative bleeding (RR = 0.129, 95% CI:0.02–0.75, I2=0.0%, P = 0.022) and pancreatitis (RR = 0.127, 95% CI:(0.04–0.43, I2=0.0%, P = 0.001) in ENBD+ LC+ LCBD group. Although operative time (WMD=32.465, 95% CI:0.468–64.61, I2=98.6%, P = 0.047) showed significant difference, sensitivity analysis didn’t confirm the robustness of the results. Futhermore, it seemed that ENBD+ LC+ LCBD group had a shorter length of postoperative hospital stay (WMD=-1.880, 95% CI:-3.063–-0.696, I2=94.4%, P = 0.002) and less expenditure of hospitalization (WMD=-430.439, 95% CI:-704.620–-156.258, I2=92.3%, P = 0.002).
Conclusions
It is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for patients with cholecystolithiasis combined with CBD stones.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Opening Fund of Engineering Research Center of Cognitive Healthcare of Zhejiang Province (No.2018KFJJ09).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Influence of DPYD*9, DPYD*6 and GSTP1 ile105val genetic polymorphisms on capecitabine and oxaliplatin (CAPOX) associated toxicities in colorectal cancer patients
Presenter: Ashok Varma
Session: Poster display session
Resources:
Abstract
99P - Patient-derived tumour model by new culture method leading to the precision medicine
Presenter: Norikatsu Miyoshi
Session: Poster display session
Resources:
Abstract
100P - Clinical impact and carcinogenic mechanism of NCAPG overexpression in colon cancer
Presenter: Kai-Yuan Lin
Session: Poster display session
Resources:
Abstract
101P - Combined cellular immunotherapy and chemotherapy improves clinical outcome and displays safety in the treatment of patients with colorectal cancer
Presenter: Chang Wang
Session: Poster display session
Resources:
Abstract
102P - Clinical features of anorectal cancer in patients with Crohn’s disease: Japanese single center study
Presenter: Kazuhiro Watanabe
Session: Poster display session
Resources:
Abstract
103P - Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy
Presenter: Yanfei Yang
Session: Poster display session
Resources:
Abstract
104P - Prognostic significance of tumour location to the oncologic outcome of colon cancer
Presenter: Sare Hosseini
Session: Poster display session
Resources:
Abstract
105P - Detection and clinical significance of circulating tumour cells in patients with rectal cancer
Presenter: Shuohui Dong
Session: Poster display session
Resources:
Abstract
106P - The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum
Presenter: Yakov Ten
Session: Poster display session
Resources:
Abstract
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract